JP2013533232A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013533232A5 JP2013533232A5 JP2013514194A JP2013514194A JP2013533232A5 JP 2013533232 A5 JP2013533232 A5 JP 2013533232A5 JP 2013514194 A JP2013514194 A JP 2013514194A JP 2013514194 A JP2013514194 A JP 2013514194A JP 2013533232 A5 JP2013533232 A5 JP 2013533232A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cancer
- composition according
- agent
- taxane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003795 chemical substances by application Substances 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 10
- 229940123237 Taxane Drugs 0.000 claims 8
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 8
- 239000002105 nanoparticle Substances 0.000 claims 7
- 102000009027 Albumins Human genes 0.000 claims 5
- 108010088751 Albumins Proteins 0.000 claims 5
- 102000014914 Carrier Proteins Human genes 0.000 claims 5
- 108010078791 Carrier Proteins Proteins 0.000 claims 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 2
- 102000008100 Human Serum Albumin Human genes 0.000 claims 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical group O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical group O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 102000003964 Histone deacetylase Human genes 0.000 claims 1
- 108090000353 Histone deacetylase Proteins 0.000 claims 1
- 102000016397 Methyltransferase Human genes 0.000 claims 1
- 108060004795 Methyltransferase Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 229960002756 azacitidine Drugs 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 229960003603 decitabine Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical group ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims 1
- 229960000237 vorinostat Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35233310P | 2010-06-07 | 2010-06-07 | |
| US61/352,333 | 2010-06-07 | ||
| US201161446909P | 2011-02-25 | 2011-02-25 | |
| US61/446,909 | 2011-02-25 | ||
| PCT/US2011/037450 WO2011156119A1 (en) | 2010-06-07 | 2011-05-20 | Combination therapy methods for treating proliferative diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016132221A Division JP2016175947A (ja) | 2010-06-07 | 2016-07-04 | 増殖性疾患を処置するための組み合わせ療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013533232A JP2013533232A (ja) | 2013-08-22 |
| JP2013533232A5 true JP2013533232A5 (enExample) | 2014-07-03 |
| JP6031437B2 JP6031437B2 (ja) | 2016-11-24 |
Family
ID=45098373
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013514194A Active JP6031437B2 (ja) | 2010-06-07 | 2011-05-20 | 増殖性疾患を処置するための組み合わせ療法 |
| JP2016132221A Withdrawn JP2016175947A (ja) | 2010-06-07 | 2016-07-04 | 増殖性疾患を処置するための組み合わせ療法 |
| JP2018025928A Pending JP2018087227A (ja) | 2010-06-07 | 2018-02-16 | 増殖性疾患を処置するための組み合わせ療法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016132221A Withdrawn JP2016175947A (ja) | 2010-06-07 | 2016-07-04 | 増殖性疾患を処置するための組み合わせ療法 |
| JP2018025928A Pending JP2018087227A (ja) | 2010-06-07 | 2018-02-16 | 増殖性疾患を処置するための組み合わせ療法 |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US20140155344A1 (enExample) |
| EP (2) | EP3056201A1 (enExample) |
| JP (3) | JP6031437B2 (enExample) |
| KR (1) | KR101850566B1 (enExample) |
| CN (2) | CN105832703A (enExample) |
| AU (2) | AU2011264590B2 (enExample) |
| BR (1) | BR112012031163A2 (enExample) |
| CA (1) | CA2801891C (enExample) |
| CO (1) | CO6670568A2 (enExample) |
| CR (1) | CR20120638A (enExample) |
| IL (2) | IL223190A0 (enExample) |
| MX (1) | MX2012014231A (enExample) |
| MY (1) | MY166014A (enExample) |
| NI (1) | NI201200181A (enExample) |
| NZ (1) | NZ707377A (enExample) |
| PH (1) | PH12012502399A1 (enExample) |
| RU (2) | RU2577278C2 (enExample) |
| SG (2) | SG185798A1 (enExample) |
| WO (1) | WO2011156119A1 (enExample) |
| ZA (1) | ZA201208820B (enExample) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| SI1585548T1 (sl) | 2002-12-09 | 2018-11-30 | Abraxis Bioscience, Llc | Sestave in metode odmerjanja farmakoloških sredstev |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| CN105288630A (zh) | 2005-02-18 | 2016-02-03 | 阿布拉科斯生物科学有限公司 | 治疗剂的组合和给予方式以及联合治疗 |
| SI1931321T1 (sl) | 2005-08-31 | 2019-07-31 | Abraxis Bioscience, Llc | Sestave, ki zajemajo slabo vodotopne farmacevtske učinkovine in antimikrobna sredstva |
| DK2117520T3 (en) | 2006-12-14 | 2019-01-07 | Abraxis Bioscience Llc | BREAST CANCER THERAPY BASED ON HORMON RECEPTOR STATUS WITH NANOPARTICLES INCLUDING TAXAN |
| AU2008260447B2 (en) * | 2007-06-01 | 2013-10-10 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
| RU2559570C2 (ru) | 2009-04-15 | 2015-08-10 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Композиции без приона на основе наночастиц и способы их получения |
| NZ602382A (en) | 2010-03-26 | 2014-11-28 | Abraxis Bioscience Llc | Methods of treatment of hepatocellular carcinoma |
| MX364637B (es) | 2010-03-29 | 2019-05-03 | Abraxis Bioscience Llc Star | Platino y nanopartículas que incluyen placlitaxel/albúmina para usarse en el trartamiento de nsclc. |
| CN105147613A (zh) | 2010-03-29 | 2015-12-16 | 阿布拉科斯生物科学有限公司 | 增强药物递送和治疗剂有效性的方法 |
| CA2801645A1 (en) | 2010-06-04 | 2011-12-08 | Abraxis Bioscience, Llc | Use of nanoparticules comprising a taxane and an albumin in the treatment of pancreatic cancer |
| CN105832703A (zh) * | 2010-06-07 | 2016-08-10 | 阿布拉科斯生物科学有限公司 | 治疗增殖性疾病的联合治疗方法 |
| SG194623A1 (en) | 2011-04-28 | 2013-12-30 | Abraxis Bioscience Llc | Intravascular delivery of nanoparticle compositions and uses thereof |
| WO2012149268A1 (en) | 2011-04-29 | 2012-11-01 | Selecta Biociences, Inc. | Tolerogenic synthetic nanocarriers for allergy therapy |
| EP2707030B1 (en) | 2011-05-09 | 2020-02-19 | Mayo Foundation For Medical Education And Research | Cancer treatments |
| SG11201401946QA (en) | 2011-11-01 | 2014-05-29 | Celgene Corp | Methods for treating cancers using oral formulations of cytidine analogs |
| AU2012352167B2 (en) | 2011-12-14 | 2017-07-27 | Abraxis Bioscience, Llc | Use of polymeric excipients for lyophilization or freezing of particles |
| AU2013327638B2 (en) | 2012-10-01 | 2018-06-14 | Mayo Foundation For Medical Education And Research | Cancer treatments |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| JP6349381B2 (ja) | 2013-03-12 | 2018-06-27 | アブラクシス バイオサイエンス， エルエルシー | 肺がんを処置する方法 |
| JP6309610B2 (ja) | 2013-03-14 | 2018-04-11 | アブラクシス バイオサイエンス， エルエルシー | 膀胱がんを処置する方法 |
| US10357483B2 (en) * | 2013-05-03 | 2019-07-23 | Selecta Biosciences, Inc. | Methods comprising dosing combinations for reducing undesired humoral immune responses |
| AU2014262164B2 (en) * | 2013-05-03 | 2020-02-27 | Selecta Biosciences, Inc. | Dosing combinations for reducing undesired humoral immune responses |
| US20160250351A1 (en) | 2014-06-13 | 2016-09-01 | Mayo Foundation For Medical Education And Research | Treating Lymphomas |
| CN106604750B (zh) | 2014-06-16 | 2021-05-07 | 梅约医学教育与研究基金会 | 治疗骨髓瘤 |
| WO2015195634A1 (en) * | 2014-06-17 | 2015-12-23 | Celgne Corporation | Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine |
| AU2015311707B2 (en) | 2014-09-07 | 2021-12-09 | Selecta Biosciences, Inc. | Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses |
| US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
| MX2017007321A (es) * | 2014-12-02 | 2017-08-25 | Celgene Corp | Terapias de combinacion. |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| EA036790B1 (ru) | 2015-06-29 | 2020-12-22 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способ лечения злокачественной пекомы |
| TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體－抗體組合物及其製造及使用方法 |
| TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
| WO2017120501A1 (en) | 2016-01-07 | 2017-07-13 | Mayo Foundation For Medical Education And Research | Methods of treating cancer with interferon |
| CN105606824B (zh) * | 2016-01-28 | 2018-04-06 | 山东省药物研究院 | 晚期乳腺癌患者外周血循环肿瘤细胞Her‑2基因的检测方法 |
| WO2017139698A1 (en) | 2016-02-12 | 2017-08-17 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
| AU2017238119A1 (en) | 2016-03-21 | 2018-10-11 | Mayo Foundation For Medical Education And Research | Methods for reducing toxicity of a chemotherapeutic drug |
| WO2017165439A1 (en) | 2016-03-21 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Methods for improving the therapeutic index for a chemotherapeutic drug |
| US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| WO2018045238A1 (en) | 2016-09-01 | 2018-03-08 | Mayo Foundation For Medical Education And Research | Methods and compositions for targeting t-cell cancers |
| KR102462041B1 (ko) | 2016-09-01 | 2022-11-02 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 암 치료용 담체－ｐｄ－ｌ１ 결합제 조성물 |
| EP3509635A1 (en) | 2016-09-06 | 2019-07-17 | Vavotar Life Sciences LLC | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
| EP3510048A1 (en) | 2016-09-06 | 2019-07-17 | Mayo Foundation for Medical Education and Research | Methods of treating pd-l1 expressing cancer |
| JP7025412B2 (ja) | 2016-09-06 | 2022-02-24 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | パクリタキセル－アルブミン－結合剤組成物並びに該組成物の使用及び製造方法 |
| WO2018067943A1 (en) * | 2016-10-07 | 2018-04-12 | Abraxis Bioscience, Llc | Methods of treating biliary tract cancer |
| CA3055936A1 (en) | 2017-03-11 | 2018-09-20 | Selecta Biosciences, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| KR20200064112A (ko) | 2017-10-03 | 2020-06-05 | 크리티테크, 인크. | 암의 치료를 위한 면역치료제의 전신 전달과 조합된 항신생물성 입자의 국소 전달 |
| CA3094453A1 (en) | 2018-03-20 | 2019-09-26 | Abraxis Bioscience, Llc | Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin |
| CN108498529A (zh) * | 2018-06-20 | 2018-09-07 | 福建师范大学 | 用于肿瘤预防治疗的DNA甲基转移酶抑制剂与cGAMP药物组合物 |
| WO2020102325A1 (en) * | 2018-11-13 | 2020-05-22 | Yee Amy | Compositions and methods of enhancing immunotherapies |
| JP2022543021A (ja) | 2019-05-29 | 2022-10-07 | ネルム コーポレーション | がんを処置する方法及び使用 |
| JP2022553426A (ja) | 2019-10-28 | 2022-12-22 | アブラクシス バイオサイエンス， エルエルシー | アルブミンおよびラパマイシンの医薬組成物 |
| EP4196106A1 (en) * | 2020-08-11 | 2023-06-21 | Auxilla Pharmaceuticals and Research LLP | A non-aqueous suspension of anticancer agent |
| TR202018770A2 (tr) * | 2020-11-23 | 2021-02-22 | Ankara Ueniversitesi | Platine Dirençli Over Kanseri Tedavisine Yönelik Yeni Bir İlaç Taşıyıcı Sistem |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| NZ502500A (en) * | 1997-06-27 | 2002-03-28 | Vivorx Pharmaceuticals Inc | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US6613753B2 (en) * | 2001-02-21 | 2003-09-02 | Supergen, Inc. | Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation |
| SI1585548T1 (sl) * | 2002-12-09 | 2018-11-30 | Abraxis Bioscience, Llc | Sestave in metode odmerjanja farmakoloških sredstev |
| US20050187148A1 (en) * | 2004-02-25 | 2005-08-25 | Yoshinori Naoe | Antitumor agent |
| US7951780B2 (en) * | 2004-02-25 | 2011-05-31 | Astellas Pharma Inc. | Antitumor agent |
| AU2006249235B2 (en) * | 2004-05-14 | 2010-11-11 | Abraxis Bioscience, Llc | Sparc and methods of use thereof |
| US20060069060A1 (en) * | 2004-09-27 | 2006-03-30 | Sanjeev Redkar | Salts of decitabine |
| US20080213399A1 (en) * | 2005-02-03 | 2008-09-04 | Topotarget Uk Limited | Combination Therapies Using Hdac Inhibitors |
| CN105288630A (zh) * | 2005-02-18 | 2016-02-03 | 阿布拉科斯生物科学有限公司 | 治疗剂的组合和给予方式以及联合治疗 |
| US20070166388A1 (en) * | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| US8735394B2 (en) * | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| BRPI0615292A8 (pt) | 2005-08-31 | 2018-03-06 | Abraxis Bioscience Llc | composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada |
| EP1942884A4 (en) * | 2005-11-04 | 2010-01-06 | Merck & Co Inc | METHOD FOR THE TREATMENT OF CANCER WITH SAHA, CARBOPLATIN AND PACLITAXEL AND OTHER COMBINATION THERAPIES |
| US20080057086A1 (en) * | 2006-09-01 | 2008-03-06 | Pharmion Corporation | Colon-targeted oral formulations of cytidine analogs |
| US8093220B2 (en) * | 2006-12-04 | 2012-01-10 | Novartis Ag | Combination of an HDAC inhibitor and an antimetabolite |
| EP3326630A3 (en) | 2007-05-03 | 2018-08-29 | Abraxis BioScience, LLC | Methods and compositions for treating pulmonary hypertension |
| MX339451B (es) * | 2008-04-03 | 2016-05-27 | Cognate 3 Llc | Composiciones y metodos para inmunoterapia. |
| WO2009126401A1 (en) | 2008-04-10 | 2009-10-15 | Abraxis Bioscience, Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
| KR20150136137A (ko) | 2008-04-10 | 2015-12-04 | 아브락시스 바이오사이언스, 엘엘씨 | 소수성 탁산 유도체의 조성물 및 그의 용도 |
| MY161593A (en) * | 2008-05-15 | 2017-04-28 | Celgene Corp | Oral formulations of cytidine analogs and methods of use thereof |
| US20100055047A1 (en) * | 2008-08-26 | 2010-03-04 | Yiyu Zou | Methods for treating bronchial premalignancy and lung cancer |
| MX2011006167A (es) * | 2008-12-11 | 2011-07-28 | Abraxis Bioscience Llc | Combinaciones y modos de administracion de agentes terapeuticos y terapia de combinacion. |
| KR20120053052A (ko) * | 2009-08-25 | 2012-05-24 | 아브락시스 바이오사이언스, 엘엘씨 | 헤지호그 억제제 및 탁산의 나노입자 조성물로의 조합 요법 |
| CN105147613A (zh) * | 2010-03-29 | 2015-12-16 | 阿布拉科斯生物科学有限公司 | 增强药物递送和治疗剂有效性的方法 |
| MX364637B (es) * | 2010-03-29 | 2019-05-03 | Abraxis Bioscience Llc Star | Platino y nanopartículas que incluyen placlitaxel/albúmina para usarse en el trartamiento de nsclc. |
| RU2621640C2 (ru) * | 2010-06-02 | 2017-06-06 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы лечения рака мочевого пузыря |
| CA2801645A1 (en) * | 2010-06-04 | 2011-12-08 | Abraxis Bioscience, Llc | Use of nanoparticules comprising a taxane and an albumin in the treatment of pancreatic cancer |
| CN105832703A (zh) * | 2010-06-07 | 2016-08-10 | 阿布拉科斯生物科学有限公司 | 治疗增殖性疾病的联合治疗方法 |
| US9149455B2 (en) * | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) * | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
-
2011
- 2011-05-20 CN CN201610059985.4A patent/CN105832703A/zh active Pending
- 2011-05-20 US US13/701,001 patent/US20140155344A1/en not_active Abandoned
- 2011-05-20 KR KR1020137000228A patent/KR101850566B1/ko active Active
- 2011-05-20 NZ NZ707377A patent/NZ707377A/en unknown
- 2011-05-20 PH PH1/2012/502399A patent/PH12012502399A1/en unknown
- 2011-05-20 BR BR112012031163A patent/BR112012031163A2/pt not_active Application Discontinuation
- 2011-05-20 SG SG2012088001A patent/SG185798A1/en unknown
- 2011-05-20 RU RU2012156903/15A patent/RU2577278C2/ru active
- 2011-05-20 AU AU2011264590A patent/AU2011264590B2/en active Active
- 2011-05-20 CA CA2801891A patent/CA2801891C/en active Active
- 2011-05-20 MY MYPI2012005255A patent/MY166014A/en unknown
- 2011-05-20 SG SG10201504590WA patent/SG10201504590WA/en unknown
- 2011-05-20 EP EP16153625.5A patent/EP3056201A1/en not_active Withdrawn
- 2011-05-20 JP JP2013514194A patent/JP6031437B2/ja active Active
- 2011-05-20 CN CN201180038243.9A patent/CN103037846B/zh active Active
- 2011-05-20 RU RU2016103126A patent/RU2016103126A/ru not_active Application Discontinuation
- 2011-05-20 WO PCT/US2011/037450 patent/WO2011156119A1/en not_active Ceased
- 2011-05-20 EP EP11792867.1A patent/EP2575774A4/en not_active Withdrawn
- 2011-05-20 MX MX2012014231A patent/MX2012014231A/es unknown
-
2012
- 2012-11-22 IL IL223190A patent/IL223190A0/en unknown
- 2012-11-22 ZA ZA2012/08820A patent/ZA201208820B/en unknown
- 2012-12-06 NI NI201200181A patent/NI201200181A/es unknown
- 2012-12-14 CR CR20120638A patent/CR20120638A/es unknown
-
2013
- 2013-01-04 CO CO13001846A patent/CO6670568A2/es unknown
- 2013-03-01 US US13/782,992 patent/US20140170228A1/en not_active Abandoned
-
2016
- 2016-07-04 JP JP2016132221A patent/JP2016175947A/ja not_active Withdrawn
- 2016-11-28 US US15/361,851 patent/US20170181998A1/en not_active Abandoned
-
2017
- 2017-03-15 AU AU2017201757A patent/AU2017201757A1/en not_active Abandoned
-
2018
- 2018-02-16 JP JP2018025928A patent/JP2018087227A/ja active Pending
- 2018-08-10 US US16/101,027 patent/US20190167629A1/en not_active Abandoned
-
2019
- 2019-10-03 IL IL26980819A patent/IL269808A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013533232A5 (enExample) | ||
| JP2013527232A5 (enExample) | ||
| RU2012156903A (ru) | Способы комбинированной терапии для лечения пролиферативных заболеваний | |
| Sun et al. | Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system | |
| Socinski et al. | Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer | |
| JP2011079858A5 (enExample) | ||
| Socinski et al. | Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer | |
| NZ708506A (en) | Methods of treating bladder cancer | |
| JP2013503174A5 (enExample) | ||
| JP2012520323A5 (enExample) | ||
| De Souza et al. | Chemotherapy dosing schedule influences drug resistance development in ovarian cancer | |
| Wang et al. | Gold nanoparticle-mediated delivery of paclitaxel and nucleic acids for cancer therapy | |
| MX2019013701A (es) | Metodos para mejorar suministro de farmacos y efectividad de agentes terapeuticos. | |
| JP2015516989A5 (enExample) | ||
| JP2008530248A5 (enExample) | ||
| HRP20160609T1 (hr) | Postupci liječenja hepatocelularnog karcinoma | |
| JP2010209081A5 (enExample) | ||
| RU2017132877A (ru) | Комбинация антагониста pd-1 и эрибулина для лечения рака | |
| Lee et al. | Paclitaxel nanosuspensions for targeted chemotherapy–nanosuspension preparation, characterization, and use | |
| JP2009515901A5 (enExample) | ||
| Argiris | Current status and future directions in induction chemotherapy for head and neck cancer | |
| JP2015510945A5 (enExample) | ||
| RU2015139515A (ru) | Комбинированное лечение | |
| CN103442708B (zh) | 治疗性处理 | |
| JP2011500650A5 (enExample) |